22nd Century Group Inc (NYSE:XXII) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “

Separately, Chardan Capital upped their price objective on 22nd Century Group from $3.50 to $11.50 and gave the company a “buy” rating in a research report on Monday.

Shares of 22nd Century Group (XXII) opened at 2.68 on Wednesday. The company’s market cap is $275.40 million. The company has a 50-day moving average of $2.77 and a 200 day moving average of $1.94. 22nd Century Group has a 12-month low of $0.81 and a 12-month high of $3.50.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/20/22nd-century-group-inc-xxii-rating-increased-to-hold-at-zacks-investment-research.html.

In other 22nd Century Group news, VP Michael Robert Moynihan sold 50,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $2.67, for a total value of $133,500.00. Following the transaction, the vice president now owns 867,220 shares of the company’s stock, valued at approximately $2,315,477.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of institutional investors have recently made changes to their positions in XXII. Vanguard Group Inc. grew its position in 22nd Century Group by 17.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,894,322 shares of the biotechnology company’s stock valued at $5,065,000 after acquiring an additional 432,450 shares during the last quarter. Virtu KCG Holdings LLC grew its position in 22nd Century Group by 300.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 126,106 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 94,650 shares during the last quarter. Northern Trust Corp grew its position in 22nd Century Group by 22.3% in the 2nd quarter. Northern Trust Corp now owns 133,797 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 24,401 shares during the last quarter. Finally, National Asset Management Inc. grew its position in 22nd Century Group by 13.7% in the 1st quarter. National Asset Management Inc. now owns 172,000 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 20,700 shares during the last quarter.

About 22nd Century Group

Receive News & Stock Ratings for 22nd Century Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group Inc and related stocks with our FREE daily email newsletter.